SELLAS names chief business and strategy officer
With over a decade of Wall Street experience following the biotechnology sector, Dr. Eckard brings to SELLAS both important industry insights and an understanding of the healthcare equity markets.
Dr. Eckard will join SELLAS from Barclays, where he was a Director and Senior Biotechnology Analyst.
Prior to joining Barclays, Dr. Eckard covered the biotechnology and specialty pharmaceuticals sectors at Citigroup, Leerink Swann and HSBC.
As a research analyst, he received several accolades including Institutional Investor’s “Best up-and-comer” and “Rising Star,” and is broadly recognized for his knowledge in immunogen-oncology.
Before his career in financial services, Dr. Eckard was in academia, conducting cancer research and teaching at the NYU School of Medicine.
He earned a BS in Biochemistry from Ohio University, along with an MS in Toxicology and a PhD in Toxicology and Carcinogenesis from the NYU School of Medicine. ■
LATEST MOVES FROM Switzerland
- Wizz Air appoints Stephen Jones as EVP and deputy CFO
- Ferrexpo appoints Simon Lockett as director
- Wolseley appoints Nadia Shouraboura as director
- Glencore appoints Martin Gilbert as director
- Wolseley appoints Kevin Murphy as CEO of Ferguson Enterprises
More inside POST
Surprising effect of consumer local identity Leadership